Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D04JTD
|
||||
Former ID |
DCL000205
|
||||
Drug Name |
PX-12
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Phase 2 | [528013] | ||
Therapeutic Class |
Anticancer Agents
|
||||
Company |
Biomira
|
||||
Structure |
Download2D MOL |
||||
Formula |
C7H12N2S2
|
||||
Canonical SMILES |
CCC(C)SSC1=NC=CN1
|
||||
InChIKey |
BPBPYQWMFCTCNG-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 141400-58-0
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
9374284, 15219811, 30422463, 57399846, 79245557, 103106749, 103564705, 113468605, 117402020, 123121574, 126460084, 135142363, 140114675, 162249061, 162310065, 162790932, 164154946, 164210775, 170364272, 174006855, 175427007, 177748841, 204361145, 210274949, 210280587, 215774935, 223392225, 223435396, 227058245, 243264143, 252156900, 252161718, 252475622
|
||||
Target and Pathway | |||||
Target(s) | Thioredoxin | Target Info | Inhibitor | [536388], [536492], [536593] | |
NetPath Pathway | IL2 Signaling Pathway | ||||
RANKL Signaling Pathway | |||||
PANTHER Pathway | Hypoxia response via HIF activation | ||||
Oxidative stress response | |||||
Pathway Interaction Database | p38 MAPK signaling pathway | ||||
Signaling events mediated by PTP1B | |||||
TNF receptor signaling pathway | |||||
PathWhiz Pathway | Purine Metabolism | ||||
References | |||||
Ref 536388 | A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clin Cancer Res. 2007 Apr 1;13(7):2109-14. | ||||
Ref 536492 | Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Jun;29(5):359-73. | ||||
Ref 536593 | 2-[(1-methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation. Mol Cancer Ther. 2008 Jan;7(1):143-51. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.